Antipsychotics – 2\textsuperscript{nd} Generation: Vraylar

Medical policy no. 59.40.00.18  
Effective Date: March 1, 2021

\textbf{Note:} New-to-market drugs included in this class based on the Apple Health Preferred Drug List are non-preferred and subject to this prior authorization (PA) criteria. Non-preferred agents in this class require an inadequate response or documented intolerance due to severe adverse reaction or contraindication to at least TWO preferred agents. If there is only one preferred agent in the class documentation of inadequate response to ONE preferred agent is needed. If a drug within this policy receives a new indication approved by the Food and Drug Administration (FDA), medical necessity for the new indication will be determined on a case-by-case basis following FDA labeling.

To see the list of the current Apple Health Preferred Drug List (AHPDL), please visit: https://www.hca.wa.gov/assets/billers-and-providers/apple-health-preferred-drug-list.xlsx

\textbf{Background:}

Cariprazine (Vraylar) is an atypical antipsychotic and is indicated for the treatment of acute manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder, and schizophrenia in adults. Cariprazine works as a partial agonist of serotonin 5-HT-1a and dopamine D2 receptors and as an antagonist of serotonin 5-HT-2A.

\textbf{Medical necessity}

<table>
<thead>
<tr>
<th>Drug</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>cariprazine (Vraylar)</td>
<td>Cariprazine may be considered medically necessary when prescribed for the treatment of:</td>
</tr>
<tr>
<td></td>
<td>• Bipolar I Disorder, acute mixed or manic episodes</td>
</tr>
<tr>
<td></td>
<td>• Depressed bipolar I disorder</td>
</tr>
<tr>
<td></td>
<td>• Schizophrenia</td>
</tr>
</tbody>
</table>

\textbf{Clinical policy:}

\textbf{Clinical Criteria}

Bipolar I Disorder, acute mixed or manic episodes  
Cariprazine may be covered when \textbf{ALL} of the following are met:

\begin{itemize}
  \item 1. Client is 18 years of age or older
  \item 2. Clients 17 years of age or younger require a second opinion review with the agency-designated mental health specialist from the Second Opinion Network (SON)
  \item 3. Client meets \textbf{ONE} of the following:
    \begin{itemize}
      \item a. History of either failure after 4 weeks, contraindication, or intolerance to \textbf{THREE} of the following oral atypical antipsychotics:
        \begin{itemize}
          \item i. Aripiprazole
          \item ii. Asenapine
          \item iii. Olanzapine
          \item iv. Paliperidone or Risperidone
        \end{itemize}
    \end{itemize}
\end{itemize}
**Policy:** Antipsychotics – 2nd Generation: Vraylar

### Criteria

<table>
<thead>
<tr>
<th>Vraylar (V)</th>
<th>Quetiapine (vi)</th>
<th>Ziprasidone (i)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Documentation that client has been taking cariprazine and is stabilized on the requested dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Client has a CrCl &gt;30mL/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Client has no severe hepatic impairment (Child Pugh Score ≥10)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If **ALL** criteria are met, approve for 6 months.

If all criteria are not met, but there are circumstances supported by clinical judgement and documentation, requests may be approved by a clinical reviewer on a case-by-case basis up to the initial authorization duration.

### Criteria (Reauthorization)

Cariprazine may be reauthorized when **ALL** of the following are met:

1. Documentation that client is stabilized on cariprazine

If **ALL** criteria are met, approve for 12 months.

If all criteria are not met, but there are circumstances supported by clinical judgement and documentation, requests may be approved by a clinical reviewer on a case-by-case basis up to the reauthorization duration.

### Depressed bipolar I disorder

Cariprazine may be covered when **ALL** of the following are met:

1. Client is 18 years of age or older
2. Clients 17 years of age or younger require a second opinion review with the agency-designated mental health specialist from the Second Opinion Network (SON)
3. Client meets **ONE** of the following:
   a. History of either failure after 4 weeks, contraindication, or intolerance to **THREE** of the following oral atypical antipsychotics:
      i. Lurasidone
      ii. Olanzapine+Fluoxetine (Combination product or individual products taken concurrently)
      iii. Quetiapine
   b. Documentation that client has been taking cariprazine and is stabilized at the requested dose
4. Client has a CrCl >30mL/min
5. Client has no severe hepatic impairment (Child Pugh Score ≥10)

If **ALL** criteria are met, approve for 6 months.

If all criteria are not met, but there are circumstances supported by clinical judgement and documentation, requests may be approved by a clinical reviewer on a case-by-case basis up to the initial authorization duration.
### Criteria (Reauthorization)

Cariprazine may be reauthorized when **ALL** of the following are met:

1. Documentation that client is stabilized on cariprazine

If **ALL** criteria are met, approve for 12 months.

If all criteria are not met, but there are circumstances supported by clinical judgement and documentation, requests may be approved by a clinical reviewer on a case-by-case basis up to the reauthorization duration.

### Schizophrenia

Cariprazine may be covered when **ALL** of the following are met:

1. Client is 18 years of age or older
2. Clients 17 years of age or younger require a second opinion review with the agency-designated mental health specialist from the Second Opinion Network (SON)
3. Client meets **ONE** of the following:
   a. History of either failure after 4 weeks, contraindication, or intolerance to **THREE** of the following oral atypical antipsychotic:
      i. Aripiprazole
      ii. Asenapine
      iii. Clozapine
      iv. Iloperidone
      v. Lurasidone
      vi. Olanzapine
      vii. Paliperidone or Risperidone
      viii. Quetiapine
      ix. Ziprasidone
   b. Documentation that client has been taking cariprazine and is stabilized on the requested dose
4. Client has a CrCl >30mL/min
5. Client has no severe hepatic impairment (Child Pugh Score ≥10)

If **ALL** criteria are met, approve for 6 months.

If all criteria are not met, but there are circumstances supported by clinical judgement and documentation, requests may be approved by a clinical reviewer on a case-by-case basis up to the initial authorization duration.

### Criteria (Reauthorization)

Cariprazine may be reauthorized when **ALL** of the following are met:

1. Documentation that client is stabilized on cariprazine

If **ALL** criteria are met, approve for 12 months.
If all criteria are not met, but there are circumstances supported by clinical judgement and documentation, requests may be approved by a clinical reviewer on a case-by-case basis up to the reauthorization duration.

Dosage and quantity limits

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose and Quantity Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bipolar I disorder, acute or mixed episodes</td>
<td>Max 6 mg per day; #30 capsules per 30 days</td>
</tr>
<tr>
<td>Depressed bipolar I disorder</td>
<td>Max 3 mg per day; #30 capsules per 30 days</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Max 6 mg per day; #30 capsules per 30 days</td>
</tr>
</tbody>
</table>

References

6. Olanzapine [prescribing information]. https://www.accessdata.fda.gov/
7. Quetiapine [prescribing information]. https://www.accessdata.fda.gov/
### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action and Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/15/2020</td>
<td>Added language to clinical criteria sections: Clients 17 years of age or younger require a second opinion review with the agency-designated mental health specialist from the Second Opinion Network (SON)</td>
</tr>
<tr>
<td>11/30/2020</td>
<td>Added link to AHPDL publication</td>
</tr>
<tr>
<td>11/12/2020</td>
<td>Added language in clinical policy section for cases which do not meet policy criteria</td>
</tr>
<tr>
<td>09/01/2020</td>
<td>Updated clinical criteria using feedback from DUR meeting.</td>
</tr>
<tr>
<td>08/19/2020</td>
<td>Approved by DUR Board</td>
</tr>
<tr>
<td>05/11/2020</td>
<td>New policy</td>
</tr>
</tbody>
</table>